A 26-year-old man receives an injection in September of an experimental Ebola vaccine being tested by the National Institute of Allergy and Infectious Diseases and GlaxoSmithKline. Until now, the two leading candidates for a vaccine to protect against the Ebola virus were being led by global pharmaceutical giant GlaxoSmithKline on the one hand, and a tiny company in Ames, Iowa, that was virtually unknown, on the other.